DMC

Unknown Company

57,900
+0.00%
Mkt Cap 2.0T
Data as of 2026-07-23 · Source: public Vietnamese market feeds

By Aveluro Research Team · Editorial policy

DMC (DMC) is a company in Vietnam's Health Care sector, listed on HOSE. The stock last traded at 57,900 VND, little changed on the session, giving a market capitalization of 2.0 trillion VND.

On valuation, DMC trades at a price-to-earnings ratio of 9.9 and a price-to-book of 1.2. That is a discount to the Health Care sector average P/E of 22.2. Return on equity of 11.7% points to modest profitability relative to the company's equity base, above the sector average of 10.4%. Trailing earnings per share stand at 5,872 VND.

Aveluro tracks 5 news items mentioning DMC. The most recent catalyst was a sector sentiment event — "Foreign Ownership Dominates Vietnam's Top Pharma Stocks: DHG, IMP, DHT". Aveluro's composite model rates DMC 10.0/10 (Strong Buy), blending news sentiment, price momentum, and fundamentals.

Average daily volume over the past 10 sessions is roughly 2,000 shares; liquidity is relatively thin, so single headlines can move the price sharply. Comparable names in the Health Care sector include AGP, AMV and APC.

Latest price
57,900 VND · +0.00%
Dominant Sentiment
Neutral · 5 Articles Analyzed
Latest catalyst
sector sentiment
Liquidity
Low
Data as of
2026-07-23

Foreign Ownership Dominates Vietnam's Top Pharma Stocks: DHG, IMP, DHT

Caveat: Not investment advice. · How Aveluro computed this: Aveluro combines extracted event facts, source credibility, ticker context, and market data. Scores are deterministic research signals, not recommendations.

10.0
Strong Buy
Sentiment
+1.00
Impact
0.30
Momentum
+0.23
Fundamentals
+0.70
Volume
1.00
10-Session Avg Vol
2.0K
Market Cap
₫2.0T
Liquidity
Low

Low liquidity — thin average daily volume may result in wider spreads and price impact on larger orders.

P/E
9.9
P/B
1.2
ROE
11.7%
ROA
10.5%
EPS
5.9K
Articles Analyzed
5
Dominant Sentiment
Neutral
Neutral 3
Positive 2
Full Analysis sector sentiment May 13, 2026
Foreign Ownership Dominates Vietnam's Top Pharma Stocks: DHG, IMP, DHT

Vietnam's top three pharma companies by market cap—DHG, IMP, and DHT—are now under foreign control or significant influence, with Taisho, Livzon, and ASKA as key shareholders. The sector is projected to double from $8-9 billion to $16 billion by 2032, driving M&A interest.

4 Neutral
Read full analysis →
Full Analysis earnings beat Apr 20, 2026
VNDirect (VND) Q1 2026 Profit Up 43% as TP Securities (ORS) Surges 1,961%

VNDirect (VND) posted Q1 2026 pre-tax profit of VND 681 billion, a 43% year-on-year increase, as part of a broader earnings release wave. TP Securities (ORS) led with a 1,961% surge to VND 42 billion, while ACBS grew 67% to VND 303 billion, highlighting divergent performance in Vietnam's securities sector amid mixed market conditions.

10 +9.8 Positive
Read full analysis →
Full Analysis m a announcement
Chinese Livzon Acquires 67.87% of Imexpharm (IMP) for VND 6,000B in Landmark Pharma M&A

IMP is now majority-owned by China's Livzon after a VND 6,000B deal for 67.87% of shares. The acquisition gives Livzon control of IMP's 12 EU-GMP production lines, a rare asset in Vietnam. The deal underscores a broader trend of foreign domination among top Vietnamese pharma firms, including DHG (Taisho), DMC (Abbott), and DHT (ASKA).

8 Neutral
Read full analysis →

Information provided for educational purposes only. Past performance does not guarantee future results. Data sourced from public Vietnamese market feeds.

Last updated: 2026-07-23T11:46:14Z.